Over the past several years, considerable focus has been placed on the need for 'biomarkers'. However, traditional biomarkers, such as CEA or CA19-9, for gastrointestinal cancer do not provide sufficient sensitivity and specificity for diagnosing cancer. Moreover, these biomarkers cannot provide information regarding the individual variability of patients. Recently, extracellular vesicles (EVs) and extracellular microRNA (miRNA) have shown potential in cancer diagnosis because tumor cells have been shown to release EVs and miRNAs, which mirror their cellular origin, into circulation. Therefore, detection of tumor-specific EVs and extracellular miRNA in body fluids from cancer patients could serve as a non-invasive liquid biopsy for cancer diagnosis and monitoring. This review explores the potential contribution of liquid biopsy using EVs and extracellular miRNA to diagnosis and monitor cancer, including an assessment of prognosis and early detection of disease recurrence in patients with cancer.
Introduction
To improve the clinical outcomes of cancer patients, early detection and accurate disease monitoring are necessary because early detection can significantly reduce cancer mortality and accurate monitoring can provide an ideal therapeutic strategy for an individual cancer patient. However, the currently available screening modalities are severely inadequate because they are expensive and involve invasive, risky and cumbersome preparatory procedures that ultimately lead to a low participation rate. Biomarkers in the blood or other body fluids are useful tools that can enable diagnosis and monitoring of diseases through a non-invasive examination at a low cost and risk. Cancer cells secrete various types of humoral factors into their microenvironment, including cytokines (1-3), chemokines (1) (2) (3) , nucleic acids (4) and extracellular vesicles (EVs) (5) (6) (7) . Recently, the study of these factors has led to a new diagnostic concept called 'liquid biopsy': blood or other body fluids provide a platform for the early diagnosis of cancer and potentially for monitoring disease progression. The term 'liquid biopsy' was originally introduced to analyze circulating tumor cells (CTCs) (8) and is now used to analyze circulating tumor DNA (ctDNA). However, the clinical use of this cell population is limited by the rarity of viable CTCs in peripheral blood, and for ctDNA analysis, it is critical to avoid contamination by DNA from normal blood cells (9) . On the other hand, conventional blood-based tumor markers, such as carcinoembryonic antigen (CEA) or CA19-9, suffer from low sensitivity, especially with respect to their use in screening for early stages or inability to distinguish aggressive from indolent tumors (10, 11) . Hence, additional biomarker resources and detection methods are required. In particular, EVs and circulating microRNAs (miRNAs), such as EV-associated miRNAs, have been attracting attention as novel tumor biomarkers to detect various cancer types and disease statuses (12, 13) . Compared with conventional tissue biopsy, EV-based liquid biopsy has several merits. EVs reflect the physiological state of their cells of origin (14) , and almost all cells actively secrete EVs that contain specific proteins and miRNAs into their microenvironment and general circulation ( Fig. 1) (7) . Therefore, EVs from cancer cells have been found in the blood and other body fluids of patients with cancer. In other words, EVs offer ease of collection with minimal discomfort to the patients and are preferred for serial collections. In addition, EVs shed from heterogeneous cancers reflect the dynamic changes that occur during disease progression and allow us to access crucial molecular information about the status of the disease. Therefore, in this review, we discuss the current challenges and future perspectives of EVs and EV-associated miRNAs as biomarkers in clinical oncology.
Extracellular vesicles contain information on the originating cell
In this article, we use the term EVs as an umbrella term for all types of vesicles present in the extracellular space. Some confusion exists in the literature regarding the terms 'microvesicles' and 'exosomes'. The difference between these two terms is generally based on size: exosomes are in the range of around 100 nm and microvesicles are in the range of 100-1000 nm. However, because EV research is still in its infancy, these definitions are flexible. Furthermore, the difference between these two terms is also based on the production pathway. Microvesicles directly bud from the plasma membrane, whereas exosomes are released via exocytosis from multivesicular bodies (MVBs) of the late endosome (7) . Some researchers use these terms according to strict definitions, whereas others use the terms interchangeably. Several years ago, the International Society for Extracellular Vesicles (ISEV) recommended that researchers use the term 'extracellular vesicles (EVs)' as an umbrella term for all types of vesicles present in the extracellular space, including exosomes, shedding vesicles, melanosomes, prostasomes and apoptotic bodies (15) . Following this recommendation, we use the term EVs throughout the paper.
EVs are molecularly complex entities that carry lipids, soluble and transmembrane proteins, and various RNA species, including mRNA, miRNA and DNA (7) . EVs serve as tools for cell-to-cell communication by transferring transmembrane proteins and soluble components of the cytosol, including mRNA and miRNAs, which have been shown to elicit various responses in the recipient cells (16) . A certain set of these molecules is commonly contained in EVs regardless of their origin (17) , but the total molecular composition of EVs varies depending on the mechanism of formation as well as the type and functional state of the cell of origin (18) . In addition, cellular stress conditions are reflected in the EV protein and RNA contents. Therefore, EVs derived from stress-exposed cells convey the stress signals in the case of stress, and damage, as well as disease to target cells (14) . For example, EVs isolated from malignant effusions of cancer patients contain tumor-specific antigens, including Her2/Neu from ovarian cancer ascites and Mart1 from patients with melanoma (19) . EVs may contain information on the identity of their parental cells, their functional state and their gene expression pattern.
Extracellular vesicles deliver cancer pathogenic components
Given their fundamental role in regulating biological processes, it is reasonable that in some contexts EVs have an important role in tumor progression. Cancer cell-derived EVs are emerging as local and systemic intercellular mediators of oncogenic information through the horizontal transfer of mRNAs, miRNAs, and proteins during tumorigenesis (6, 20) . Many studies have shown that cancer cells release a wide variety of cancer cell-derived EVs that influence the behavior of cells in the primary tumor microenvironment and at metastatic sites (20) . Therefore, cancer cell-derived EVs play roles in facilitating tumor growth and invasion, angiogenesis, metastasis, chemoresistance, immune evasion and escape from cell death. A pioneering study on the important role of cancer cell-derived EVs in tumor progression was performed by Al-Nedawi et al. in 2008 (21) . They revealed that glioblastoma-derived EVs support propagation of malignancy by transferring EGFRvIII. EGFRvIII can be packaged into EVs from EGFRvIII-expressing glioma cells and transferred to EGFRvIII-negative cancer cells, activating mitogenactivated protein kinase (MAPK) and AKT signaling pathways in recipient cells, and thereby enhancing their survival and tumor growth (21) . These isolated EV-associated proteins constitute a 'cancer signature', which may help in improving the diagnosis and treatment of cancer patients. Malignant tumor phenotypes are not only determined by cancer cells but also by the tumor microenvironment (22, 23) . These microenvironments consist of various cell types, such as endothelial cells, epithelial cells, fibroblasts, lymphocytes and inflammatory cells. Increasing evidence has implicated EV-delivered 'cancer signature' components in cell-cell communication, which is an important and complex process that allows tumor cells to become malignant and influence their environment. For example, endothelial cells have been described as recipients of cancer cellderived EVs in many types of cancer models, resulting in the activation of angiogenesis, which favors tumor growth and dissemination. Several reports have shown that EV-associated miR-9-5p (24), -23a-3p (25), -210-3p (26, 27) and some miRNAs regulate the behavior of endothelial cells and contribute to tumor angiogenesis. Cancerassociated fibroblasts (CAFs), which are present in tumor microenvironments, actively participate in the growth and invasiveness of tumor cells by secreting growth factors, cytokines and various inflammatory mediators (28) . A recent study by Zhao et al. showed that EVs derived from cancer-associated fibroblasts (CAFs) enhanced the growth of prostate cancer cells in nutrientdeprived environments by regulating metabolism in a Krasindependent manner (29) . These EVs inhibited mitochondrial metabolism as well as upregulated glycolysis and reductive glutamine carboxylation in PDAC cells. In a follow-up study by Achreja et al., it was shown that EVs could supply substantial free metabolites to the TCA cycle (30) . Moreover, the role of cancer cell-derived EVs in metastasis has been extensively addressed over the past several years. Several publications indicate the important role of EVs in the preparation of the pre-metastatic niche. An important study from Peinado et al. demonstrated that EVs derived from melanoma cells educate bone marrow cells towards a pro-metastatic phenotype via horizontal transfer of MET, thereby establishing their role in mediating communication between tumor cells and normal cells in distant organs (31). Fong et al. reported that cancer cells can suppress glucose uptake by normal cells in the pre-metastatic niche by secreting EV-associated miR-122 (32) . Hence, miR-122, which taken up by normal cells in the pre-metastatic niche, targets PKM2 and represses glycolytic metabolism, thereby lowering glucose utilization by normal cells and allowing glucose use by growing cancer cells (32) . Moreover, cancer-derived EVs mediate brain metastasis through the destruction of the blood-brain barrier (BBB) (33, 34) . Brain metastasis is an important cause of mortality in breast cancer patients. The BBB tightly regulates the permeability of the central nervous system to the vascular system (35) (36) (37) . Thus, BBB destruction is one of the key steps in allowing the extravasation of cancer cells during brain metastasis (35) . Tominaga et al. demonstrated that EVs derived from a brain metastatic breast cancer cell line, which contain miR-181c-5p, induced the destruction of the BBB (34) . miR-181c-5p negatively regulates 3-phosphoinositidedependent protein kinase-1 (PDPK1) and causes degradation of phosphorylated cofilin and severing of actin filaments (34) . In ovarian cancer, cancer-derived EVs are also important in peritoneal dissemination (38) . Recently, Yokoi et al. showed that EVs from highly metastatic ovarian cancer cells, which carry MMP1 mRNA, strongly promote the metastatic potential of moderately metastatic cells and induce comprehensive apoptosis in human mesothelial cells, causing destruction of the peritoneal mesothelium barrier and increasing the risk of metastasis (38) . These findings raise the question of how EVs are directed to specific metastatic organs, enabling organotropic metastatic growth. One of the reasons why EVs are directed to specific metastatic organs is because EVs have their own protein 'zipcodes' that address them to specific target organs, thus determining metastatic organotropism (39) . Hoshino et al. described a distinct integrin expression pattern in EVs that correlates with cancer cells' metastatic organotropism. The EV-associated integrins α 6 β 4 and α 6 β 1 are associated with lung metastasis, while α V β 5 is associated with liver metastasis. These reports indicate that tumor-derived EVs that contain specific proteins, miRNAs and mRNAs are secreted into tumor microenvironments and circulation, resulting in the promotion of cancer progression. Therefore, EVs have an important role in the messenger of cancer pathogenic components in cell-to-cell communication. In addition, EV-associated proteins, including EV surface proteins and miRNAs (or mRNAs) derived from tumors, also have important role as the signatures of cancer cells in liquid biopsy for disease diagnosis.
Extracellular vesicle-associated proteins as a novel resource for liquid biopsy
Because EVs are found in all body fluids (7) and are recognized as important messengers of cancer pathogenic components in cell-tocell communication (16) , EVs are strong candidates for use in liquid biopsy for cancer diagnosis. The protein phenotype of EVs can be a signature of cancer cells and used to identify disease-related biomarkers. However, the detection of EVs is extremely challenging because many vesicles have a diameter of~100 nm, a low refractive index, are highly heterogeneous (18) , and are sensitive to collection and handling conditions (40) (41) (42) (43) (44) (45) (46) . Therefore, in this section, we focus on detection methods that exploit the specificity and sensitivity associated with antibody-based assays to characterize the protein phenotype of EVs. Logozzi and colleagues have described an ELISA-based method (Exotest) for the selective detection of EVs (47) . This study is the first report on an easy assay for the quantification of EVs. However, Exotest requires extensive sample purification by ultracentrifugation and large amounts of sample. Exotest was designed as an ELISA to capture and quantify EVs that possess EV marker proteins (CD63 and Rab-5b) and a tumor-associated protein on their surfaces (caveolin-1). The researchers evaluated the levels of CD63 and Rab5b double positive EVs or caveolin-1 and Rab-5b double positive EVs from the plasma of melanoma patients and healthy donors using Exotest. Their results indicated that CD63 and Rab-5b double positive EVs or caveolin-1 and Rab-5b double positive EVs were significantly increased in melanoma patients compared with healthy donors. This study suggested that the detection of plasma EVs carrying tumor-associated antigens might represent a novel tool for the clinical management of cancer patients.
We established a highly sensitive and rapid analytical assay system named 'ExoScreen' to directly profile circulating EVs from serum samples of patients with colorectal cancer (48) . In this system, EVs are captured by two types of antibodies and detected by photosensitizer-beads. ExoScreen technology enabled the detection of both CD9 and CD63 present on EVs in 5 μl of healthy donor serum without purification steps. Furthermore, we found that CD147 and CD9 double-positive EVs were significantly higher in serum from CRC patients (n = 194) than in serum from healthy donors (n = 191). A portion of the sera from CRC patients, including Stage I and II, were positive for CD147. Despite the normal values of CEA and CA19-9, which are conventional CRC biomarkers, ExoScreen was able to detect cancer-specific EVs in Stage I cancer patient serum. Furthermore, the CD147-positive EVs in cancer patient sera were largely reduced after surgery, suggesting that the reduced signal of CD147 obtained from ExoScreen was originated from cancer-derived EVs. These results indicate that ExoScreen can be used to detect EV-associated cancer biomarkers and is superior for the detection of CRC patients of early stage to conventional biomarkers CEA and CA19-9.
Jørgensen et al. established a novel microarray platform called 'EV Array' (49, 50) . It is capable of detecting and phenotyping EVs from unpurified starting material in a high throughput manner. Micrometer-sized spots of capturing antibodies against known EV surface antigens are printed in a customized spot setup. The captured vesicles are detected using a cocktail of antibodies against the tetraspanins CD9, CD63 and CD81. Using this system, the authors reported that a combined top-30 protein marker panel can separate the non-small cell lung cancer group from the control group with an area under the curve (AUC) of 0.83 (CI: 0.77-0.90, 0.75 sensitivity and 0.76 specificity) (51) . This technology offers a high-throughput approach for phenotyping EVs without any enrichment or purification prior to analysis.
Shao et al. developed a multiplex microfluidics approach with an ultrasensitive detector system for EVs based on micro-nuclear magnetic resonance (μNMR) (52) . For ease of clinical application, a microfluidic device was developed that can label EVs with antibodybound magnetic nanoparticles (MNPs), filter out unbound antibodies or MNPs on the basis of particle size, and detect labeled EVs using an integrated microcoil. This system can differentiate glioblastoma multiforme (GBM) EVs from non-tumor host cell-derived EVs. They also showed that circulating GBM EVs could be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. These results indicate that disease-specific EVs are an important class of biomarkers for monitoring therapy. In addition, they reported a surface plasmon resonance-based assay for label-free, high-throughput EV protein analyses (53) . The approach uses a chip called a nano-plasmonic exosome (nPLEX) sensor, which consists of an array of periodic nanoholes patterned in a gold film. Using nPLEX to analyze ascites samples from ovarian cancer patients, they showed that EpCAM and CD24 distinguished ovarian cancer-derived EVs from EVs originating from nonmalignant cells in ascites samples. Although, compared with conventional methods, the nPLEX technology and μNMR technology offer highly sensitive detection technologies, large cohorts in prospective trials are required to establish the clinical utility of these technologies.
Zhao et al. also developed a simple microfluidic device called the 'ExoSearch' chip that quantitatively isolates EVs using immunomagnetic beads (54) . The 'ExoSearch' chip was used for liquid biopsy of ovarian cancer by measuring three EV-associated tumor protein markers, CA-125, EpCam and CD24. When measuring these markers in 15 patients with ovarian cancer and five healthy donors, the ExoSearch chip assay was highly accurate (AUC = 1.0) in discriminating plasma EVs from ovarian cancer patients vs. healthy individuals. ExoSearch enables multiplexed quantification of marker combinations in one sample with improved speed and has the potential to quantify EVs in a small volume of blood (20 μl).
Liang et al. developed a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumor-derived EVs from as little as 1 μl of plasma without an EV isolation step (55) . They identified a pancreatic cancer EV biomarker, ephrin type-A receptor 2 (EphA2), and demonstrated that the assay for EphA2-EVs distinguishes pancreatic cancer patients from pancreatitis patients and healthy donors. Furthermore, they indicated a strong association between circulating EphA2-EV and pancreatic cancer, including early-stage pancreatic cancer, suggesting the potential utility of EphA2-EV as an early detection marker.
These studies indicate that a liquid biopsy using circulating EVs can clarify tumor characteristics without performing an invasive biopsy of the tumor. Although the studies described above are encouraging, a number of aspects remain to be delineated to fully harness the diagnostic and prognostic potential of EVs. One of these fundamental aspects is that EVs are usually used following isolation steps by ultracentrifugation. This well-developed isolation method has been shown to be effective and can process up to 100 ml of samples. Unfortunately, this method is time consuming (~6 h) and therefore is unsuitable for daily clinical practice. However, some of the methods introduced above (e.g., ExoScreen, EV array, ExoSearch, nPES assay, etc.) do not require an EV isolation step. Hence, these methods are suitable for use in daily clinical practice. Another fundamental aspect, which is imperative to address, is standardization, including pre-analytical conditions, and isolation procedures. Such standardization will provide a consensus for protocols and thereby facilitate unbiased comparisons of results from different studies across laboratories. Furthermore, standardization will greatly aid in the development of robust clinical assays. The next challenge, before using EVs in a diagnostic manner, is to select the most optimal methods, concerning sample requirements, apparatuses, and analysis accessibility. In addition, many studies have reported target markers for cancer diagnosis (Table 1) , and selection of the most optimal combination of these target markers is essential to several of the methods.
Extracellular vesicle-associated miRNAs as a novel resource for liquid biopsy
In addition to EV-associated proteins, EV-associated miRNAs are attractive as potential biomarkers. miRNAs are known to be aberrantly expressed in tumors, with some functioning as tumor suppressors and others acting as oncogenes (oncomiRs), depending on which genes or pathways they regulate (56) . Although miRNA expression patterns in tumors can be used for cancer diagnosis, a tissue sample is required, necessitating a biopsy, excision or another invasive procedure, such as fine needle aspiration. One breakthrough regarding cancer diagnosis using miRNA was the discovery of miRNA in EVs (57). Valadi et al. showed that mouse and human mast cell-derived EVs contain miRNA. After this report, in 2008, three independent studies demonstrated that miRNAs are released into the circulation and exist there in a remarkably stable form, thereby suggesting that extracellular miRNAs may carry diseasespecific signatures that could be exploited as non-invasive biomarkers (58) (59) (60) . In particular, miRNAs in body fluid, which are not associated with vesicles, were reported to show differential stability to treatment by RNase A (61), suggesting that EV-associated miRNAs are preferable as biological specimens for developing diagnostic biomarkers because of their stability in body fluid. Furthermore, the innate properties of miRNAs make them highly attractive as potential biomarkers. For example, miRNAs can be readily detected in small volume samples using specific and sensitive quantitative real-time PCR (qRT-PCR); have been isolated from most body fluids, including plasma, serum, saliva, urine, breast milk, tears and semen; and are known to exist in a highly stable, cell-free form (59, (62) (63) (64) . Thereafter, many studies have attempted to identify EV-associated miRNAs with diagnostic, prognostic or predictive relevance in body fluids from patients with various diseases. In this section, we summarize the potential of EV-associated miRNAs in clinical applications. Table 2 shows representative studies reporting dysregulated miRNA in body fluid-derived EVs from patients. As shown above, many studies have evaluated the feasibility of EV-associated miRNAs for detecting early stage cancer and also as prognostic or predictive markers. For example, Madhavan et al. revealed that in EVs derived from pancreatic cancer patients, including early stage patients, a panel of miRNAs, including miR-3976, miR-1246, miR-4306 and miR-4644, were increased (65) . Moreover, a combined evaluation of a panel of EV-associated proteins and miRNAs can increase the sensitivity and specificity of pancreatic cancer diagnosis (65) . Another recent study reported highly sensitive non-invasive biomarkers for the early detection of non-small cell lung cancer (NSCLC) (66). Jin et al. performed RNA-sequence analysis to identify candidates and validate adenocarcinoma and squamous cell carcinoma (SCC)-specific miRNAs from 46 Stage I NSCLC patients and 42 healthy individuals (66) . They found EV-associated miRNAs for diagnostic biomarkers of NSCLC (let-7b-5p, miR-21-5p, miR-24-3p and miR-486-5p), adenocarcinoma (miR-181-5p, miR30a-3p, miR-30e-3p and miR-361-5p) and SCC (miR-10b-5p, miR15b-5p and miR-320b). More importantly, the diagnostic accuracy of combination miRNA panels exhibited an area under the curve (AUC) value of 0.899, 0.936 and 0.911 for the detection of NSCLC, adenocarcinoma and SCC, respectively. For CRC diagnosis, Ogata et al. performed a global miRNA screen in CRC and healthy control serum samples (67) . In this study, microarray analyses of miRNAs in EV-enriched fractions of serum samples from 88 primary CRC patients and 11 healthy controls were performed. They found that the serum EV levels of 16 miRNAs were higher in CRC patient sera. In the validation study, the levels of seven of the miRNAs, namely, let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223 and miR23a, were significantly higher in serum EVs from CRC patients than those from healthy donors. Elevations of these miRNA levels were even observed in early stage (TNM Stage I) CRC samples. Despite the promising reports described above, there are problems to be solved before the development of EV-associated miRNA-based diagnostics can occur. The main issue is the need to isolate EVs from body fluid and extract miRNA from isolated EVs. Many studies have extracted miRNAs from body fluid without the EV isolation step (68) (69) (70) (71) (72) . They analyzed circulating miRNAs, including EV-associated miRNAs. However, the unique properties of EV-associated miRNAs, including their stability in circulation, their reproducible detection and, most importantly, the fact that they reflect the properties of cancer cells, may render them useful for the development of highly sensitive diagnostic strategies for rapid and non-invasive monitoring of the pathological condition of cancer patients. In addition, there is no consensus on suitable small RNA reference genes that could be used as internal controls for biological variability; current protocols call for samples to be processed from identical input volumes and then corrected for technical variability using spiked-in synthetic non-human (Caenorhabditis elegans) miRNA as a normalizing control. Use of 'unchanged' miRNAs as endogenous controls has been proposed by some investigators, but biological variability may preclude this approach and no consensus has been reached to date. Although some issues remain, miRNA in EVs from body fluid will be a great, novel liquid biopsy tool for the diagnosis of cancer or for the monitoring of cancer during treatment.
Conclusion
For cancer patients, sampling a biopsy for diagnosis or analysis is an uncomfortable and somewhat risky procedure. Nonetheless, a histological evaluation of tumor tissues obtained from biopsies is the gold standard of diagnosis at present. Moreover, the biopsy of overt metastases is an invasive procedure limited to certain locations and not easily acceptable in the clinic. In addition, the biopsy of one or two accessible metastases may not be representative. To avoid tumor biopsies by invasive methods, EV-associated proteins and miRNAs in body fluids could serve as a liquid biopsy that is useful for a variety of tumors. Furthermore, as introduced above, many studies showed that EVs and EV-associated miRNAs have potential as biomarker for early detection of cancer and monitor of cancer compared with conventional blood-based tumor markers. Although liquid biopsy technology is still in its early stage, ex vivo analysis of EV-associated proteins and miRNAs in body fluids can be expected to provide biomarker-discovery platforms and facilitate disease diagnosis and monitoring. We believe that diagnosis can be possible with non-invasive methods via analysis of EV-associated proteins and miRNAs in body fluids in the near future.
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